Edgewise Therapeutics, Inc. financial data

Symbol
EWTX on Nasdaq
Industry
Pharmaceutical Preparations
Location
1715 38 Th St, Boulder, CO
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Mar 3, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.73K % +28.9%
Debt-to-equity 4.52 % -28.5%
Return On Equity -26.9 % +16.2%
Return On Assets -25.7 % +14.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 95.2M shares +1.93%
Common Stock, Shares, Outstanding 94.8M shares +34.6%
Entity Public Float 1.4B USD +263%
Common Stock, Value, Issued 9K USD +28.6%
Weighted Average Number of Shares Outstanding, Basic 92.4M shares +45%
Weighted Average Number of Shares Outstanding, Diluted 92.4M shares +45%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 127M USD +39.7%
General and Administrative Expense 31.9M USD +35.9%
Operating Income (Loss) -159M USD -38.9%
Net Income (Loss) Attributable to Parent -134M USD -33.6%
Earnings Per Share, Basic -1.45 USD/shares +7.64%
Earnings Per Share, Diluted -1.45 USD/shares +7.64%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 41.7M USD -51.6%
Assets, Current 475M USD +45.4%
Property, Plant and Equipment, Net 9.5M USD -9%
Operating Lease, Right-of-Use Asset 1.57M USD -30.2%
Other Assets, Noncurrent 262K USD -24.7%
Assets 487M USD +43.2%
Accounts Payable, Current 5.58M USD +38.6%
Employee-related Liabilities, Current 10.1M USD +76.6%
Accrued Liabilities, Current 7.23M USD +19.1%
Liabilities, Current 23.9M USD +42.3%
Operating Lease, Liability, Noncurrent 3.74M USD -15.6%
Liabilities 27.6M USD +30.2%
Accumulated Other Comprehensive Income (Loss), Net of Tax 420K USD +324%
Retained Earnings (Accumulated Deficit) -379M USD -54.7%
Stockholders' Equity Attributable to Parent 459M USD +44%
Liabilities and Equity 487M USD +43.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -28.6M USD -25.3%
Net Cash Provided by (Used in) Financing Activities 241M USD
Net Cash Provided by (Used in) Investing Activities -268M USD -647%
Common Stock, Shares Authorized 1B shares 0%
Common Stock, Shares, Issued 94.8M shares +34.6%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -55.8M USD -313%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 41.7M USD -51.6%
Deferred Tax Assets, Valuation Allowance 112M USD +60.4%
Deferred Tax Assets, Gross 112M USD +60.4%
Depreciation 2.07M USD +33.4%
Payments to Acquire Property, Plant, and Equipment 297K USD -93.2%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -133M USD -35.2%
Property, Plant and Equipment, Gross 14.2M USD +8.65%
Operating Lease, Liability, Current 996K USD +1.63%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 200M shares 0%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 837M USD +48.6%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 24.7M USD +40.7%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%